This retrospective study of ours not only further validates immunotherapy + antiangiogenic therapy + chemotherapy as a therapy that is a relatively better clinical strategy in advanced NSCLC patients after EGFR-TKIs resistance, but also provides the groundbreaking finding that such patients with brain metastases can achieve better efficacy with immune-related combination therapy than with conventional chemotherapy + antiangiogenic therapy, with the difference being statistically significant (median PFS, 6.44 vs 4.21 months, P = 0.022). This evidence concerns the gene EGFR and non-small cell lung carcinoma.